Piramal Pharma Gears Up for Growth with Rs 1,000 Crore Investment

Piramal Pharma (PPL) is charting an ambitious growth trajectory with a planned investment of approximately Rs 1,000 crore over the next 18 months. This strategic allocation of funds is geared towards facilitating brownfield expansion and consolidation initiatives, reflecting the company's commitment to fortify its position in the pharmaceutical sector.

In a bid to enhance operational efficiency, around Rs 330 crore is earmarked for deployment during the second half of the financial year. This allocation aims to optimize the newly added brownfield capacities, ensuring a more productive operational framework.

The company's stellar performance in the first half of the current fiscal year is evident across its three operational verticals—Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare (ICH), all of which reported impressive double-digit growth.

To facilitate its growth plans, the company recently successfully raised Rs 1,050 crore through a rights issue. While a substantial portion of these funds was directed towards debt repayment, a strategic allocation has also been made for capital expenditure

News b Rahul Yeligetti